Schering Corporation

Merck Sharp + Dohme Corp.

Harry R Davis

Duane A Burnett

Scott W Altmann

Michael P Graziano

Xiaorui Yao

Maureen Laverty

Kevin B Alton

Enrico P Veltri

John T Strony

Rudyard J Ress

John W Clader

Stuart B Rosenblum

Wayne D Vaccaro

Songnian Lin

Yusheng Xiong

Jay Weinstein

James E Patrick

Jose M Castro-Perez

Anima Ghosal

Swapan K Chowdhury

Wenqing Feng

Hong-Ping Guan

Shmuel Zbaida

Deborra E Mullins

Teddy Kosoglou

Robert M Iannucci

Liangsu Wang

Nathan P Yumibe

Margaret Van Heek

Gilles J Picard

Samuel E Engel

Douglas G Johns

Stephen F Previs

Thomas P Roddy

Sheng-Ping Wang

Gilles Jean Picard

Steven F Previs

Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.

Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor

The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.

Use of azetidinone compounds

The present invention is directed to the use of sterol absorption inhibiting compounds, pharmaceutical compositions thereof, therapeutic combinations and their use in combination with other lipid lowering agents to treat or prevent sitosterolemia and/or to lower the concentration of sterol(s) other than cholesterol in plasma or tissue of a mammal. Methods of treating or preventing vascular disease and coronary events also are provided.

Use of substituted azetidinone compounds for the treatment of sitosterolemia

The present invention provides therapeutic combinations and methods including at least one sterol or 5&#x3b1;-stanol absorption inhibitor that can be useful for treating xanthomas.

Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors

The present invention provides methods of treating diabetes and associated conditions by administering a composition including at least one sterol or 5&#x3b1;-stanol absorption inhibitor or compositions or therapeutic combinations including: (a) at least one antidiabetic medication; and (b) at least one sterol or 5&#x3b1;-stanol absorption inhibitor.

Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors

The present invention provides methods for the treatment of obesity using sterol or 5&#x3b1;-stanol absorption inhibitors and compositions and therapeutic combinations including sterol or 5&#x3b1;-stanol absorption inhibitors and at least one obesity control medication.

Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors

Hypocholesterolemic substituted 2-azetidinone compounds of the formula:are disclosed, as well as a methods of lowering cholesterol by administering said compounds, pharmaceutical compositions containing them, and the combination of a substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis.

Substituted 2-azetidinones useful as hypocholesterolemic agents

Hypocholesterolemic sugar-substituted 2-azetidinones are disclosed, as well as a method of lowering cholesterol by administering said compounds, pharmaceutical compositions containing them, and the combination of a sugar-substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis.

Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents

Combination of a cholesterol biosynthesis inhibitor and a .beta.-lactam

A method of inhibiting the binding of PDGF using compounds of the formula I ##STR1## useful in the treatment of atherosclerosis, cancer, retinal detachment, pulmonary fibrosis, arthritis, psoriasis and glomerulonephritis, and restenosis following angioplasty or vascular surgery is disclosed. Also disclosed are pharmaceutical compositions and novel PDGF inhibitory compounds of the formula ##STR2## or a pharmaceutically acceptable addition salt thereof, useful in the treatment of atherosclerosis, cancer, retinal detachment, pulmonary fibrosis, arthritis, psoriasis and glomerulonephritis, and restenosis following angioplasty or vascular surgery.

Inhibitors of platelet-derived growth factor

Growing community of inventors

Berkeley Heights, NJ, United States of America

Harry R Davis